Serio Bianca, De Novellis Danilo, Gorrese Marisa, Bertolini Angela, Manzo Paola, Picone Francesca, Della Corte Anna Maria, Marcucci Rossella, Morini Denise, Rizzo Michela, Guariglia Roberto, Luponio Serena, Scala Pasqualina, Verdesca Francesco, Sessa Anna Maria, Velino Francesca, De Leucio Martina, Langella Maddalena, Giudice Valentina, Selleri Carmine
Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84131 Salerno, Italy.
Department of Medicine, Surgery, and Dentistry, University of Salerno, 84081 Baronissi, Italy.
Hematol Rep. 2025 Sep 10;17(5):46. doi: 10.3390/hematolrep17050046.
: Hematogones, B cell precursors, are considered a clock of bone marrow reconstitution after chemotherapy and hematopoietic stem cell transplantation (HSCT). : In this retrospective observational monocentric study, we investigated the prognostic role of hematogone expansion after allogeneic HSCT and its association with clinical and molecular features. : Using a cut-off value of 0.1%, hematogones were detected in 60% of patients at the first re-evaluation after HSCT (median, 2.4%; range, 0.2-9.0%) and in 63% of subjects at the most recent evaluation (MRR) (median, 1.4%; range, 0.1-5.1%). In particular, prolonged hematogone expansion was associated with longer overall survival ( = 0.0043) and relapse-free survival ( = 0.0002). No associations were described between hematogone frequency and stem cell sources or acute or chronic graft versus host disease incidence. : In conclusion, our results confirmed that hematogones mirrored bone marrow fitness and reconstitution ability; thus, they could be used as a prognostic marker of HSCT outcomes.
造血前体细胞（Hematogones），即B细胞前体，被认为是化疗和造血干细胞移植（HSCT）后骨髓重建的一个指标。在这项回顾性观察性单中心研究中，我们调查了异基因造血干细胞移植后造血前体细胞扩增的预后作用及其与临床和分子特征的关联。以0.1%为临界值，在造血干细胞移植后的首次重新评估中，60%的患者检测到造血前体细胞（中位数为2.4%；范围为0.2 - 9.0%），在最近一次评估（MRR）中，63%的受试者检测到造血前体细胞（中位数为1.4%；范围为0.1 - 5.1%）。特别是，造血前体细胞的长期扩增与更长的总生存期（P = 0.0043）和无复发生存期（P = 0.0002）相关。未发现造血前体细胞频率与干细胞来源或急性或慢性移植物抗宿主病发生率之间存在关联。总之，我们的结果证实，造血前体细胞反映了骨髓的健康状况和重建能力；因此，它们可作为造血干细胞移植结果的预后标志物。
